OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
May 01, 2023
Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.
January 19, 2023
In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.
November 01, 2022
Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.
September 15, 2022
A systematic review of studies published from 1998-2021 provides insight into the potential long-term quality of life improvements achieved after undergoing parathyroidectomy in patients who primary hyperparathyroidism, with results shedding light on the quality of life changes up to 10 years after parathyroidectomy.
September 02, 2022
An analysis of more than 11 million women in China details associations between preconception thyroid dysfunction, measured as thyrotropin levels, and delayed time to pregnancy and risk of spontaneous abortion.
August 09, 2022
New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
July 30, 2022
Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
July 20, 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
July 07, 2022
A study of more than 15,000 patients from a national insurance research database suggests older patients with hypothyroidism had an 81% increase in risk of having dementia compared to their counterparts without hypothyroidism.
June 20, 2022
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.